Filgrastim for the Promotion of Collateral Growth in Patients With CAD
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study in humans with stable coronary artery disease (CAD) treatable by
PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of
subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF
(Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.
Phase:
N/A
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Collaborators:
Swiss Heart Foundation Swiss National Science Foundation